title: Recombinant mouse cytomegalovirus expressing a ligand for the NKG2D receptor is attenuated and has improved vaccine properties.
abstract: Human CMV (HCMV) is a major cause of morbidity and mortality in both congenitally infected and immunocompromised individuals. Development of an effective HCMV vaccine would help protect these vulnerable groups. NK group 2, member D (NKG2D) is a potent activating receptor expressed by cells of the innate and adaptive immune systems. Its importance in HCMV immune surveillance is indicated by the elaborative evasion mechanisms evolved by the virus to avoid NKG2D. In order to study this signaling pathway, we engineered a recombinant mouse CMV expressing the high-affinity NKG2D ligand RAE-1γ (RAE-1γMCMV). Expression of RAE-1γ by MCMV resulted in profound virus attenuation in vivo and lower latent viral DNA loads. RAE-1γMCMV infection was efficiently controlled by immunodeficient hosts, including mice lacking type I interferon receptors or immunosuppressed by sublethal γ-irradiation. Features of MCMV infection in neonates were also diminished. Despite tight innate immune control, RAE-1γMCMV infection elicited strong and long-lasting protective immunity. Maternal RAE-1γMCMV immunization protected neonatal mice from MCMV disease via placental transfer of antiviral Abs. Despite strong selective pressure, the RAE-1γ transgene did not exhibit sequence variation following infection. Together, our results indicate that use of a recombinant virus encoding the ligand for an activating NK cell receptor could be a powerful approach to developing a safe and immunogenic HCMV vaccine.
authors.affiliation: Department of Histology and Embryology, Faculty of Medicine, University of Rijeka, Rijeka, Croatia.
authors.forename: Irena
authors.initials: I
authors.lastname: Slavuljica
authors.forename: Andreas
authors.initials: A
authors.lastname: Busche
authors.forename: Marina
authors.initials: M
authors.lastname: Babić
authors.forename: Maja
authors.initials: M
authors.lastname: Mitrović
authors.forename: Iva
authors.initials: I
authors.lastname: Gašparović
authors.forename: Durđica
authors.initials: D
authors.lastname: Cekinović
authors.forename: Elitza
authors.initials: E
authors.lastname: Markova Car
authors.forename: Ester
authors.initials: E
authors.lastname: Pernjak Pugel
authors.forename: Ana
authors.initials: A
authors.lastname: Ciković
authors.forename: Vanda Juranić
authors.initials: VJ
authors.lastname: Lisnić
authors.forename: William J
authors.initials: WJ
authors.lastname: Britt
authors.forename: Ulrich
authors.initials: U
authors.lastname: Koszinowski
authors.forename: Martin
authors.initials: M
authors.lastname: Messerle
authors.forename: Astrid
authors.initials: A
authors.lastname: Krmpotić
authors.forename: Stipan
authors.initials: S
authors.lastname: Jonjić
mesh_terms: D000818:Animals; D000831:Animals, Newborn; D001483:Base Sequence; D003586:Cytomegalovirus Infections / Q000276:immunology / Q000517:prevention & control; D017931:DNA Primers / Q000235:genetics; D005260:Female; D005818:Genetic Engineering; D006566:Herpesviridae Infections / Q000276:immunology / Q000517:prevention & control; D006801:Humans; D007112:Immunity, Maternally-Acquired; D007694:Killer Cells, Natural / Q000276:immunology; D008024:Ligands; D008565:Membrane Proteins / Q000235:genetics* / Q000276:immunology*; D051379:Mice; D008807:Mice, Inbred BALB C; D018146:Muromegalovirus / Q000235:genetics* / Q000276:immunology*; D055655:NK Cell Lectin-Like Receptor Subfamily K / Q000235:genetics* / Q000276:immunology*; D011247:Pregnancy; D014613:Vaccines, Attenuated / Q000235:genetics / Q000276:immunology; D014614:Vaccines, Synthetic / Q000235:genetics / Q000276:immunology; D014765:Viral Vaccines / Q000235:genetics* / Q000276:immunology*
chemical_list: D017931:DNA Primers; C527086:Klrk1 protein, mouse; D008024:Ligands; D008565:Membrane Proteins; D055655:NK Cell Lectin-Like Receptor Subfamily K; C491217:Raet1c protein, mouse; D014613:Vaccines, Attenuated; D014614:Vaccines, Synthetic; D014765:Viral Vaccines